Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease

Clinical Breast Cancer

Volumn 7, Issue 3, 2006, Pages 254-261

  Robinson, Andrew G ^a,b   Turbin, Dmitry ^a   Thomson, Tom ^a   Yorida, Erika ^a   Ellard, Susan ^a   Bajdik, Chris ^a   Huntsman, David ^a   Gelmon, Karen ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b Northeastern Ontario Regional Cancer Centre   (Canada)

Author keywords

HER1; HER2; Hormone receptor status; Tissue microarray

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR; NAVELBINE; PHOSPHATASE; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL PROTOCOL; CORRELATION ANALYSIS; DATA BASE; DISEASE FREE INTERVAL; FACTORIAL ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 33748987350     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.038     Document Type: Article

References (29)

1. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
2. Wiseman SM, Makretsov N, Nielsen TO, et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 2005; 103:1770-1777.
3. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19:2722-2730.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
5. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med 2005; 353:1673-1684.
7. Perez EA, Suman VJ, Davidson NE, et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant tastuzumab trial. J Clin Oncol 2005; 23(16 suppl):17s (Abstract #556).
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
9. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001; 12(suppl 1):S3-S8.
10. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-354.
11. Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 2002; 29:4-10.
12. Pinkas-Kramarski R, Shelly M, Guarino BC, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 1998; 18:6090-6101.
13. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002; 62:3151-3158.
14. Agus DB, Akita AM, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-137.
15. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93:852-857.
16. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-127.
17. Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003; 97:545-553.
18. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of inter-laboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002; 117:723-728.
19. Reiner A, Neumeister B, Spona J, et al. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 1990; 50:7057-7061.
20. Vogel CL, Cobleigh MA, Tripathy D, et al. First-line herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61(suppl 2):37-42.
21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
22. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26(4 suppl 12):60-70. Review.
23. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10:6650-5655.
24. Smith BL, Chin D, Maltzman W, et al. The efficacy of herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 2004; 91:1190-1194.
25. Blackwell KL, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol 2005; 23(16 suppl):193s (Abstract #3004).
26. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200:290-297.
27. DiGiovanna M, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005; 23:1152-1160.
28. Kim C, Bryant J, Horne Z, et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Bread Cancer Res Treat 2005; 94(suppl 1):S6 (Abstract #46).
29. Slamon D, Eiermann W, Robert et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 94(suppl 1):S5 (Abstract #1).